{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:34:39Z","timestamp":1793208879137,"version":"4.5.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>\n                    Oral etoposide has been given as palliative treatment for pediatric patients with relapsed\/refractory malignancies. There is limited literature regarding the efficacy of oral etoposide for relapsed\/refractory pediatric malignancies, and even less on its treatment burden for patients and families. We conducted a single-institution retrospective review evaluating patients with relapsed\/refractory pediatric malignancies treated with single-agent oral etoposide over an 11-year period. Clinical efficacy and treatment burden measures were collected. Seventy six patients received at least one dose of oral etoposide. Median event-free survival was 47 days (95% CI: 25-68\u00a0d). Median overall survival was 113 days (95% CI: 73-149\u00a0d). Forty eight patients (63%) had imaging performed; 20 (41%) had stable disease (SD) lasting 11 to 1286 days (median 134\u00a0d) as their best response. There was a reduction in the number of clinic visits (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.02), hospitalizations (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.02), and hospital length of stay (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.01) compared with the most recent prior cancer treatment. Our experience suggests that palliative oral etoposide benefits pediatric patients with relapsed\/refractory malignancies based on imaging documenting SD lasting a median of 3 months in a significant proportion of patients, and a reduction in treatment burden compared with their most recent prior cancer treatment.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000003285","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:19Z","timestamp":1790622019000},"page":"e434-e438","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Palliative Oral Etoposide on Survival and Treatment Burden in Patients With Relapsed\/Refractory Pediatric Malignancies"],"prefix":"10.1097","volume":"48","author":[{"given":"Yannan J.","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Lenzen","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Reichek","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Walz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyang","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walterhouse","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sokol","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"e29204","DOI":"10.1002\/pbc.29204","article-title":"Oral etoposide as a single agent in childhood and young adult cancer in England: still a poorly evaluated palliative treatment","volume":"68","author":"Fraser","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00043426-200003000-00008","article-title":"Ten-day schedule oral etoposide therapy in advanced childhood malignancies","volume":"22","author":"Schiavetti","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1096-911X(199707)29:1<28::AID-MPO5>3.0.CO;2-U","article-title":"Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors","volume":"29","author":"Needle","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/S0959-8049(97)00201-3","article-title":"Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children\u2019s Cancer Study Group (UKCCSG)","volume":"33","author":"Davidson","year":"1997","journal-title":"Eur J Cancer"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/pbc.10393","article-title":"Oral etoposide for recurrent\/progressive sarcomas of childhood","volume":"42","author":"Kebudi","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5301\/tj.5000419","article-title":"Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents","volume":"102","author":"Podda","year":"2016","journal-title":"Tumor"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1200\/JCO.1999.17.10.3221","article-title":"Oral etoposide for refractory and relapsed neuroblastoma","volume":"17","author":"Kushner","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:00:33Z","timestamp":1793206833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003285","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2026-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}